Observational studyScientific reports2025
Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From liver to cardiovascular system: the MASLD-ASCVD continuum.Internal and emergency medicine · 2026Review
- MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice.Current hypertension reports · 2026Review
- HFpEF and MASLD: converging mechanisms and clinical implications.Nature reviews. Cardiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Previous population-based studies have demonstrated differences in cardiovascular events according to the new classification of steatotic liver disease (SLD). However, detailed data on coronary artery status have not been presented. We aimed to investigate the association between subtypes of SLD and coronary artery status using findings from coronary computed tomography angiography (CCTA). We analyzed 8622 asymptomatic individuals without coronary artery disease (CAD) who underwent both abdominal ultrasonography and CCTA. Study participants were divided into four groups: 934 in the no SLD without cardiometabolic (CM) criteria group, 4811 in the no SLD with CM criteria group, 2494 in the metabolic dysfunction-associated steatotic liver disease (MASLD) group, and 252 in the MASLD with increased alcohol intake (Met-ALD) group. Obstructive CAD was defined as coronary arterial stenosis ≥ 50%. Compared with the no SLD without CM group, the no SLD with CM, MASLD, and Met-ALD groups were significantly associated with any coronary plaque (multivariable-adjusted OR 2.05 [95% CI 1.67-2.52], 2.71 [2.18-3.35], and 2.36 [1.69-3.31], respectively); calcified plaques (1.97 [1.59-2.43], 2.54 [2.04-3.16], and 2.10 [1.49-2.96], respectively); non-calcified plaques (2.04 [1.28-3.25], 2.42 [1.51-3.89], and 3.26 [1.73-6.13], respectively); and obstructive CAD (2.57 [1.53-4.32], 3.64 [2.15-6.16], and 3.51 [1.73-7.10], respectively) (p for all < 0.05). In addition, the inverse probability of treatment weighting (IPTW) analyses showed similar ORs for coronary plaques and obstructive CAD. Additionally, higher steatosis-associated fibrosis estimator (SAFE) was strongly associated with all atherosclerotic plaques and obstructive CAD. This association remained significant after multivariable adjustment and IPTW analyses. Subtypes of SLD had significant, yet different strengths of associations with subclinical coronary atherosclerosis. SAFE score classification effectively stratified the distinct associations with subclinical atherosclerosis in subjects with MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.